SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $1.05 billion market cap biotech company, recently executed stock sales totaling $43,440. According to an SEC filing, Songjiang sold 4,000 shares of common stock over two days in December. The stock has shown strong momentum recently, gaining 11.5% in the past week, though it remains down 56.6% year-to-date.
The transactions were carried out under a Rule 10b5-1 trading plan, which was adopted in September 2024. On December 19, Songjiang sold 2,000 shares at a weighted average price of $10.82, with prices ranging from $10.61 to $11.35. The following day, another 2,000 shares were sold at a weighted average price of $10.9, with transaction prices varying from $10.39 to $11.11. According to InvestingPro analysis, GYRE is currently trading above its Fair Value, with multiple metrics indicating high valuation multiples.
Following these transactions, Songjiang indirectly owns 2,934,467 shares through his spouse. The company maintains a strong liquidity position with a current ratio of 3.72, indicating solid financial health despite not being profitable in the last twelve months. InvestingPro subscribers can access 7 additional key insights about GYRE's financial position and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.